-$1.91 EPS Expected for Sarepta Therapeutics Inc (NASDAQ:SRPT) This Quarter

Brokerages predict that Sarepta Therapeutics Inc (NASDAQ:SRPT) will post earnings of ($1.91) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Sarepta Therapeutics’ earnings, with the lowest EPS estimate coming in at ($2.18) and the highest estimate coming in at ($1.77). Sarepta Therapeutics posted earnings of ($0.85) per share during the same quarter last year, which suggests a negative year over year growth rate of 124.7%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, February 26th.

According to Zacks, analysts expect that Sarepta Therapeutics will report full-year earnings of ($8.41) per share for the current financial year, with EPS estimates ranging from ($8.53) to ($8.29). For the next fiscal year, analysts anticipate that the business will report earnings of ($5.54) per share, with EPS estimates ranging from ($7.75) to ($2.32). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Sarepta Therapeutics.

A number of analysts have recently weighed in on SRPT shares. Cantor Fitzgerald upped their price target on shares of Sarepta Therapeutics from $175.00 to $211.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. HC Wainwright upped their price target on shares of Sarepta Therapeutics from $160.00 to $260.00 in a research note on Friday, December 13th. Royal Bank of Canada reduced their price target on shares of Sarepta Therapeutics from $215.00 to $200.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Goldman Sachs Group reaffirmed a “buy” rating and issued a $180.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, December 24th. Finally, Bank of America reaffirmed a “buy” rating and issued a $187.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $197.81.

In related news, CFO Sandesh Mahatme sold 125,000 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $125.50, for a total transaction of $15,687,500.00. Following the completion of the sale, the chief financial officer now directly owns 34,498 shares of the company’s stock, valued at $4,329,499. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David T. Howton sold 25,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $105.00, for a total transaction of $2,625,000.00. Following the sale, the executive vice president now directly owns 24,388 shares of the company’s stock, valued at $2,560,740. The disclosure for this sale can be found here. Over the last three months, insiders have sold 192,000 shares of company stock valued at $23,583,500. Company insiders own 6.60% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. lifted its stake in Sarepta Therapeutics by 34.6% during the third quarter. Envestnet Asset Management Inc. now owns 4,024 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 1,034 shares during the last quarter. Appleton Partners Inc. MA acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $268,000. Voya Investment Management LLC raised its holdings in shares of Sarepta Therapeutics by 10.3% during the third quarter. Voya Investment Management LLC now owns 38,062 shares of the biotechnology company’s stock valued at $2,867,000 after acquiring an additional 3,553 shares during the period. Atlantic Union Bankshares Corp acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $258,000. Finally, DNB Asset Management AS acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $1,386,000. 97.73% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:SRPT traded up $0.39 during trading on Tuesday, reaching $125.42. The company had a trading volume of 405,508 shares. The firm’s fifty day moving average is $123.92 and its 200 day moving average is $107.48. Sarepta Therapeutics has a twelve month low of $72.05 and a twelve month high of $158.80.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Further Reading: What are economic reports?

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit